Corbus Pharmaceuticals Holdings, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a nine-month net loss of $95.76 million and significantly higher operating expenses driven by expanded research and development activity.

Key Highlights

  • Nine-month net loss: $95,760 thousand for the nine months ended September 30, 2026, compared to $57,982 thousand in the same period of 2025, according to the filing.
  • Q3 2026 net loss: $37,754 thousand for the three months ended September 30, 2026, versus $23,342 thousand in Q3 2025.
  • R&D expenses: Research and development costs totaled $85,241 thousand for the nine months ended September 30, 2026, up from $51,689 thousand in the prior-year period.
  • Cash and investments: The company reported $30,246 thousand in cash and cash equivalents and $85,091 thousand in investments as of September 30, 2026.
  • Accumulated deficit: The accumulated deficit reached $651,190 thousand as of September 30, 2026, compared to $555,430 thousand at December 31, 2025.
  • Shares outstanding: 20,606,760 shares of common stock were issued and outstanding as of November 6, 2026, up from 17,611,511 at December 31, 2025.
  • Equity raised: The company issued common stock raising net proceeds of $27,620 thousand during the nine months ended September 30, 2026.

Corbus Pharmaceuticals: Q3 2026 Financial Results and Balance Sheet Position

According to the Form 10-Q filed by Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), total operating expenses for the nine months ended September 30, 2026 were $99,318 thousand, compared to $63,344 thousand for the same period in 2025. Research and development expenses accounted for the majority of that increase, rising to $85,241 thousand from $51,689 thousand year-over-year. General and administrative expenses also increased, reaching $14,077 thousand for the nine months versus $11,655 thousand in the comparable 2025 period.

The filing reports a net loss per share, basic and diluted, of $4.87 for the nine months ended September 30, 2026, compared to $4.73 in the prior-year period. For Q3 2026 alone, the net loss per share was $1.81, versus $1.90 in Q3 2025. The weighted average shares outstanding for the nine-month period rose to 19,658,506 from 12,250,315 in 2025, reflecting the company's equity issuances during the period. Total other income, net, which includes interest and investment income, was $3,558 thousand for the nine months ended September 30, 2026, down from $5,362 thousand in the same 2025 period.

As of September 30, 2026, the company reported total assets of $122,902 thousand and total liabilities of $38,144 thousand, resulting in total stockholders' equity of $84,758 thousand. This compares to total stockholders' equity of $147,503 thousand at December 31, 2025. The company also recorded stock-based compensation expense of $5,530 thousand during the nine months ended September 30, 2026. Restricted cash of $385 thousand was listed as a noncurrent asset at September 30, 2026, while no noncurrent restricted cash was reported at December 31, 2025.

What Was Disclosed

Corbus Pharmaceuticals disclosed its unaudited financial results for the quarter and nine months ended September 30, 2026, showing higher net losses and operating expenses year-over-year, primarily from increased R&D spending, alongside reduced total assets and stockholders' equity compared to year-end 2025.